Dulaglutide vs Tirzepatide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Dulaglutide or Tirzepatide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Dulaglutide and Tirzepatide?
The ~18-percentage-point weight loss gap (22.5% vs. ~3-4%) represents a generational difference - tirzepatide's dual incretin mechanism delivers fundamentally greater metabolic efficacy than single-target GLP-1 agonism.
Evidence Comparison
Tirzepatide: SURMOUNT-1 22.5% weight loss, SURPASS trials showing superior A1c reduction vs. all comparators. Dulaglutide: REWIND positive CVOT, ~3-4% weight loss. Tirzepatide vastly superior on metabolic endpoints; dulaglutide has the more mature CVOT.
Evidence Context Favoring Dulaglutide
Established CV risk reduction is the primary treatment goal and the REWIND dataset provides the needed evidence anchor.
Evidence Context Favoring Tirzepatide
Maximum weight loss and glycemic control where tirzepatide's dual mechanism delivers unambiguously superior metabolic outcomes.
Side-by-Side Snapshot
| Evidence grade | Dulaglutide: Level A Tirzepatide: Level A |
|---|---|
| Research status | Dulaglutide: FDA Approved Tirzepatide: FDA Approved |
| Primary category | Dulaglutide: Weight Loss & Metabolic Tirzepatide: Weight Loss & Metabolic |
| Cited studies | Dulaglutide: 3 Tirzepatide: 5 |